Faruqi & Faruqi Reminds Investors of Deadline for Soleno Therapeutics Securities Class Action
Faruqi & Faruqi, LLP is reminding investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Soleno Therapeutics (SLNO). The lawsuit alleges that the company and its executives made false or misleading statements regarding the safety concerns of DCCR, a drug in its Phase 3 clinical trial program.
Tickers: $SLNO
Topics: class action clinical trial safety concerns investor rights misleading statements securities litigation